Friday, April 20, 2012

Pfizer and CIM partner to form Philippine Clinical Mycology Network

A group of health professionals, mostly medical technologists, gathered together for the first meeting of the Philippine Clinical Mycology Network which aims to promote the best practice in the fight against fungal infections. The event which started on this evening, April 20, at the Cebu Parklane Hotel, will continue tomorrow, April 21, 2012 at the Cebu Institute of Medicine.

Welcoming the delegates (which came from various parts of the country) in behalf of Dr. Josefina Poblete, President and Chair of the Board of Cebu Institute of Medicine (CIM) was CIM's College Secretary, Dr. Corazon Meneses.

Dr. Virginia Mesola, one of the primemovers of this collaborative CME Project of CIM and Pfizer, gave the course overview. Prior to the overview, she discussed the vision of the network which was to advocate "the best management practices in invasive fungal infections especially in the resource-limited setting". She likewise shared the group's history, mission and action plan.

Dr. Mitzi Marie Montebon Chua, the other thinktank of this undertaking gave a short lecture on the Epidemiology and Early Recognition of Candida Infections.

Mr. Jimson Pantojan was the Master of Ceremonies.

The project is set to continue tomorrow with introductory lectures on fungi, identification of mold and yeast colonies as well as sensitivity testing.

Awaiting the delegates also are laboratory sessions demonstrating mold colonies and slide culture as well as the identification of Candida species and Antifungal Susceptibility Tests.

The activity will be capped tomorrow with a lecture on the management of invasive fungal infections.

The other lecturers are: Dr. Narciso Tapia and Ms. Myldred Completo, RMT.

Assisting the delegates in the laboratory sessions are RMTs Lorenzo Lozano, Reynaldo Manzanares, Rachel Yu, Regie Sayson and the CIM Laboratory Staff and Faculty.

This scientific meeting is being made possible by Pfizer, makers of Diflucan (Fluconazole), Vfend (Voriconazole) and Eraxis (Anidulafungin) and the Cebu Institute of Medicine.